MTN-034/REACH (Reversing the Epidemic in Africa with Choices in HIV Prevention) – A Phase IIa trial that seeks to understand the HIV prevention needs and preferences of adolescent girls and young women in sub-Saharan Africa, who are among those most vulnerable to HIV. Specifically, REACH is evaluating how adolescent girls and young women use the monthly dapivirine vaginal ring and Truvada® as daily PrEP (pre-exposure prophylaxis), and their preferences for either or both approaches after using each for six months. REACH will also collect much needed information on the safety of the approaches in these populations. The study, which began in February 2019, will enroll 300 adolescent girls and young women ages 16-21 at four trial sites in South Africa, Uganda and Zimbabwe, and is expected to be completed late 2021.
Q&A About REACH
20-July-2021
Study finds adolescent girls and young women in Africa will use HIV prevention products
15-July-2021
REACH-ing Beyond Expectations
21-April-2020
About the REACH Study (MTN-034)
6-December-2019
New study aims to empower teen girls and young women with choices in HIV prevention
7-February-2019
See Also
HIV prevention dapivirine vaginal ring found safe and acceptable in US adolescent girls
25-July-2017
Meeting Report: Stakeholders consultation on REACH (MTN-034)
December-2016